Abstract

PHARMACOVIGILANCE PERSPECTIVE IN ENDOMETRIOSIS: A FOCUS ON SAFETY AND THERAPEUTICS MONITORING

*Nakshatra S. Deokate, Rutuja S. Barange, Janhvi L. Uikey, Prof. Nikita V. Mahalle, Dr. Harigopal S. Sawarkar

.

Abstract

The presence of endometrial-like tissue outside the uterus cavity is the hallmark of endometriosis, a chronic, estrogen-dependent gynecological illness that lowers quality of life, causes discomfort, and impairs fertility in women of reproductive age. Hormonal therapy, analgesics, and surgical procedures are used to treat endometriosis; each of these treatments has the risk of adverse drug reactions (ADRs). Pharmacovigilance, which involves ongoing monitoring, ADR identification, and reporting, is essential to guaranteeing the safe and efficient use of these treatments. The underreporting of drug-induced side effects is still a significant problem in clinical practice, even with the abundance of available treatment alternatives. In order to enhance patient safety and therapeutic results, this article emphasizes the significance of pharmacovigilance in detecting, assessing, and averting negative effects associated with medications used to treat endometriosis.

Keywords: Endometriosis, Pharmacovigilance, Hormonal Therapy, Drug Monitoring, ovarian cancer in Women's Health.